Wednesday, August 14, 2019

ProMIS Neurosciences (PMN:CA)

Strengthening Drug Portfolio by Adding Novel Alzheimer's Antibodies

ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).

Cosme Ordonez, MD, Ph.D., Senior Life Sciences Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

• Identification of novel drug candidates for the treatment of Alzheimer's disease.  Q2/2019, ProMIS Neurosciences identified several antibody drug candidates targeting the protein Tau, which is a primary pharmaceutical target for the treatment of Alzheimer's disease.
• Robust drug portfolio. ProMIS has now developed antibodies against toxic oligomers derived from two primary Alzheimer's targets, Tau and Amyloid beta. In addition, the company's drug portfolio includes...
  

  
  

  
  

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in full report.  NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.